On Demand Treatment of Reflux Disease

Aflurax Versus Nexium Given on Demand to Patients With Gastro-esophageal Reflux Disease.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00184522

Enrollment

Registered

2005-09-16

Start date

2002-08-31

Completion date

2004-12-31

Last updated

2011-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroesophageal Reflux

Keywords

Gastroesophageal Reflux, Esomeprazole, Drug treatment

Brief summary

A comparison of the effect of on demand treatment with a pectin-containing natural product (Aflurax) with that esomeprazole (Nexium)

Detailed description

A randomized, controlled, open trial comparing the symptomatic effect of a pectin-containing product (Aflurax) with that of esomeprazole (Nexium 20 mg) given on-demand for 6 weeks.

Interventions

DRUGAflurax

DRUGesomeprazole

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Mild and moderate reflux symptoms Age \> 17 years Informed consent -

Exclusion criteria

Other conditions that might explain the symptoms Abuse of drugs or alcohol \-

Design outcomes

Primary

Measure	Time frame
Symptomatic relief	—

Secondary

Measure	Time frame
Overall satisfaction	—

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026